FDA slams Incyte's PD-1 over single-arm study, low response and trial deaths
The ever-growing PD-1 landscape could see a new entrant as an Incyte program is slated for an FDA decision next month. But first, the biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
